Travere Therapeutics Names Bradley Campbell CEO

Travere Therapeutics Inc. announced that Eric Dube, Ph.D., will step down as president and chief executive officer (CEO), with the Company’s Board of Directors unanimously appointing Bradley L. Campbell, former president and CEO of Amicus Therapeutics, to succeed him as president and CEO and join the Board, effective December 1, 2026.

Dube will continue in the role until that date and remain employed by the Company as an executive advisor through February 15, 2027, to support an orderly transition.

“Leading Travere has been the greatest privilege of my career,” said Dube. Since becoming president and CEO in January 2019, he has guided Travere’s evolution into a leading rare disease company. Under his leadership, the Company achieved regulatory approvals in IgA nephropathy and focal segmental glomerulosclerosis (FSGS), expanded its pipeline and capabilities, and reinforced a culture grounded in patients, purpose and performance.

About Incoming CEO Bradley Campbell

According to Gary Lyons, chairman of the Travere Board of Directors, “The Board believes Bradley could not be a better fit to build on Travere’s momentum, work alongside our talented leadership team and advance the Company’s mission through its next phase of growth.”

Campbell brings more than 25 years of biopharmaceutical experience, much of it focused on developing and delivering transformative medicines for people living with rare diseases.

Over nearly 20 years at Amicus, he held roles of increasing responsibility before becoming CEO in 2022. During his tenure as CEO, Amicus experienced significant commercial growth and evolved from a single-product company into a multi-franchise global rare disease organization.

Earlier in his career, Campbell held commercial and business development roles at Genzyme and Bristol-Myers Squibb. He currently serves on boards and advisory bodies, including the Advisory Board of the Duke-Margolis Institute for Health Policy.

Commenting on his appointment, Campbell said, “I am honored to have the opportunity to lead Travere at such an important moment in the Company’s evolution. I have long admired Travere’s commitment to the rare disease community, its strong purpose-driven culture and the extraordinary results Eric and the team have delivered for communities with the greatest unmet needs. I see an exciting opportunity to build on that momentum, reach more people living with rare disease and continue creating meaningful value for all stakeholders.”